Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma-Reference-Cited by-同舟云学术

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma

Published:2015-10-21 Issue:11 Volume:90 Page:1041-1046
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

El-Galaly Tarec Christoffer¹²,Villa Diego³,Alzahrani Musa⁴⁵,Hansen Jakob Werner⁶,Sehn Laurie H.³,Wilson Don⁷,de Nully Brown Peter⁶,Loft Annika⁸,Iyer Victor⁹,Johnsen Hans Erik¹²,Savage Kerry J.³,Connors Joseph M.³,Hutchings Martin⁶

Affiliation:

1. Department of Hematology; Aalborg University Hospital; Aalborg Denmark

2. Clinical Cancer Research Center, Aalborg University Hospital; Aalborg Denmark

3. Division of Medical Oncology; British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia; Vancouver BC Canada

4. Department of Hematology, Faculty of Medicine; University of British Columbia; Vancouver BC Canada

5. King Saud University; Riyadh Saudi Arabia

6. Department of Hematology; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark

7. Department of Functional Imaging; British Columbia Cancer Agency and the University of British Columbia; Vancouver BC Canada

8. Department of Clinical Physiology, Nuclear Medicine & PET; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark

9. Department of Nuclear Medicine; Aalborg University Hospital; Aalborg Denmark

Funder

Research Council of the Northern Region of Denmark and F Hoffmann-La Roche

Publisher

Wiley

Subject

Hematology

Reference40 articles.

1. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project;Armitage;J Clin Oncol,1998

2. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era;Ziepert;J Clin Oncol,2010

3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

4. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60);Pfreundschuh;Lancet Oncol,2008

5. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system;Blood Neoplasia;2024-09

2. Diffuse large B-cell lymphoma in peri-implant tissues following lumbar spinal fusion surgery: A case report and literature review;Asian Journal of Surgery;2024-07

3. Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma;Cytometry Part B: Clinical Cytometry;2024-06-21

4. PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients;Frontiers in Oncology;2024-06-05

5. Extranodal diffuse large B-cell lymphoma presenting with extensive organ involvement;BMJ Case Reports;2024-06